PREVENTING MORBIDITY IN FIRST EPISODE SCHIZOPHRENIA

预防首发精神分裂症的发病

• 批准号: 7608232
• 负责人: DELBERT G ROBINSON
• 金额: $ 1.47万
• 依托单位: FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7608232
• 关键词: Address; Antipsychotic Agents; Brain; Chronic; Computer Retrieval of Information on Scientific Projects Database; Dopamine D2 Receptor; Funding; Generations; Grant; Institution; Longitudinal Studies; Methods; Morbidity - disease rate; New Agents; Outcome; Patients; Pharmaceutical Preparations; Population; Research; Research Personnel; Resistance; Resources; Sampling; Schizophrenia; Serotonin; Source; Time; United States National Institutes of Health; base; first episode schizophrenia; improved; neuroimaging; prevent; response

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. There is some evidence that the second generation antipsychotic drugs may have superior efficacy in these outcome domains. However, these newer agents have been studied primarily in chronic and/or treatment resistant patient samples and there are virtually no long term studies or studies comparing the new drugs with one another. We propose to study them in the population which has the potential for maximum responsiveness and long term benefit-patients with schizophrenia who are being treated for the first time. We also propose to incorporate neuroimaging methods to evaluate the contribution of structural brain alterations, dopamine (D2) receptor occupancy and serotonin function to variability in response to treatment. The results will provide a basis for informed treatment choices for clinicians as well as address the crucial question of the potential of the new treatments to improve the longitudinal course of this devastating illness.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 有一些证据表明，第二代抗精神病药物可能在这些结果领域具有更优异的疗效。 然而，这些较新的药物主要在慢性和/或治疗耐药的患者样本中进行研究，并且实际上没有长期研究或将新药相互比较的研究。 我们建议在具有最大反应潜力和长期受益的人群中进行研究——首次接受治疗的精神分裂症患者。我们还建议采用神经影像学方法来评估大脑结构改变、多巴胺 (D2) 受体占用和血清素功能对治疗反应变异性的影响。 研究结果将为临床医生做出明智的治疗选择提供基础，并解决新疗法改善这种毁灭性疾病的纵向病程的潜力这一关键问题。